Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Phathom Pharmaceuticals (PHAT) Cash from Operations (2022 - 2025)

Phathom Pharmaceuticals (PHAT) has disclosed Cash from Operations for 4 consecutive years, with 5001000.0 as the latest value for Q4 2025.

  • On a quarterly basis, Cash from Operations rose 92.12% to 5001000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was 166775000.0, a 37.48% increase, with the full-year FY2025 number at 166775000.0, up 37.48% from a year prior.
  • Cash from Operations was 5001000.0 for Q4 2025 at Phathom Pharmaceuticals, up from 14115000.0 in the prior quarter.
  • In the past five years, Cash from Operations ranged from a high of 5001000.0 in Q4 2025 to a low of 84930000.0 in Q1 2025.
  • A 4-year average of 44853437.5 and a median of 42419000.0 in 2022 define the central range for Cash from Operations.
  • Peak YoY movement for Cash from Operations: plummeted 218.56% in 2024, then surged 92.12% in 2025.
  • Phathom Pharmaceuticals' Cash from Operations stood at 41041000.0 in 2022, then fell by 6.72% to 43797000.0 in 2023, then tumbled by 44.89% to 63456000.0 in 2024, then soared by 92.12% to 5001000.0 in 2025.
  • Per Business Quant, the three most recent readings for PHAT's Cash from Operations are 5001000.0 (Q4 2025), 14115000.0 (Q3 2025), and 62729000.0 (Q2 2025).